Mast cells play a critical role in the development of the allergic response. Upon activation by allergens and IgE via the high affinity receptor for IgE (FcRI), these cells release histamine and other functional mediators that initiate and propagate immediate hypersensitivity reactions. Mast cells also secrete cytokines that can regulate immune activity. These processes are controlled, in whole or part, by increases in intracellular Ca 2+ induced by the FcRI. We show here that N-(4-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide (BTP2), a pyrazole derivative, inhibits activation-induced Ca 2+ influx in the rat basophil cell line RBL-2H3 and in bone marrow-derived mast cells (BMMCs), without affecting global tyrosine phosphorylation of cellular proteins or phosphorylation of the mitogen-activated protein kinases Erk1/2, JNK and p38. BTP2 also inhibits activation-induced degranulation and secretion of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-13, tumor necrosis factor (TNF)-␣, and granulocyte macrophage-colony stimulating factor (GM-CSF) by BMMCs, which correlates with the inhibition of Nuclear Factor of Activated T cells (NFAT) translocation. In vivo, BTP2 inhibits antigen-induced histamine release. Structure-activity relationship analysis indicates that substitution at the C3 or C5 position of the pyrazole moiety on BTP2 (5-trifluoromethyl-3-methyl-pyrazole or 3-trifluoromethyl-5-methyl-pyrazole, respectively) affected its activity, with the trifluoromethyl group at the C3 position being critical to its activity. We conclude that BTP2 and related compounds may be potent modulators of mast cell responses and potentially useful for the treatment of symptoms of allergic inflammation.
a b s t r a c t
Mast cells play a critical role in the development of the allergic response. Upon activation by allergens and IgE via the high affinity receptor for IgE (FcRI), these cells release histamine and other functional mediators that initiate and propagate immediate hypersensitivity reactions. Mast cells also secrete cytokines that can regulate immune activity. These processes are controlled, in whole or part, by increases in intracellular Ca 2+ induced by the FcRI. We show here that N-(4-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide (BTP2), a pyrazole derivative, inhibits activation-induced Ca 2+ influx in the rat basophil cell line RBL-2H3 and in bone marrow-derived mast cells (BMMCs), without affecting global tyrosine phosphorylation of cellular proteins or phosphorylation of the mitogen-activated protein kinases Erk1/2, JNK and p38. BTP2 also inhibits activation-induced degranulation and secretion of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-13, tumor necrosis factor (TNF)-␣, and granulocyte macrophage-colony stimulating factor (GM-CSF) by BMMCs, which correlates with the inhibition of Nuclear Factor of Activated T cells (NFAT) translocation. In vivo, BTP2 inhibits antigen-induced histamine release. Structure-activity relationship analysis indicates that substitution at the C3 or C5 position of the pyrazole moiety on BTP2 (5-trifluoromethyl-3-methyl-pyrazole or 3-trifluoromethyl-5-methyl-pyrazole, respectively) affected its activity, with the trifluoromethyl group at the C3 position being critical to its activity. We conclude that BTP2 and related compounds may be potent modulators of mast cell responses and potentially useful for the treatment of symptoms of allergic inflammation.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Mast cells are integral members of the immune system. They are implicated in host responses to pathogens, autoimmune diseases, fibrosis, and wound healing. In addition, mast cells are the central effector cells in pathogenesis of allergic diseases, including anaphylaxis and allergic asthma. This is due, in large part, to the interaction between IgE and its receptor on mast cells, the FcRI. Aggregation of the FcRI by polyvalent allergen recognized by bound IgE activates mast cells, subsequently initiating an immediate hypersensitivity reaction, as well as a late-phase reaction. The immediate reaction includes the degranulation of preformed mediators and the release of rapidly synthesized lipid mediators. These mediators contribute to many allergic symptoms, ranging from erythema and edema to bronchospasm and mucous secretion in the lower respiratory tract. Late-phase reactions occur 6-24 h after the immediate reaction and are mediated by cytokines and chemokines. The effects of these reactions include edema and leukocytic influx which contribute to persistent asthma (Stone et al., 2010) .
FcRI-triggered biphasic increase in cytosolic calcium (Ca 2+ ) is an essential step during mast cell activation and in the generation of productive mast cell responses, particularly degranulation. The FcRI is triggered by IgE and antigen aggregation, which initiates several signaling pathways, activating phospholipase C␥ (PLC␥). PLC␥ cleaves phosphatidylinositol 4,5-bisphosphate and generates the secondary messengers inositol triphosphate (IP 3 ) and diacylglycerol. Thereafter, a very small, transient cytosolic Ca 2+ rises via Ca 2+ efflux from IP 3 -sensitive intracellular Ca 2+ stores and a subsequent sustained Ca 2+ influx across the plasma membrane through CRAC channels is produced, and Ca 2+ -dependent transcription factors are activated (Feske, 2007; Gwack et al., 2007; Ishikawa et al., 2003) . The close correlation between Ca 2+ mobilization, especially in the form of store-operated Ca 2+ entry, and gene expression of chemokines and cytokines underscores the importance of cytosolic Ca 2+ increases for mast cell function. Moreover, Ca 2+ mobilization is central for driving the degranulation of histamine-containing vesicles and de novo synthesis of lipid mediators (Di Capite and Parekh, 2009; Scharenberg and Kinet, 1998; Turner and Kinet, 1999) . In fact, mice lacking the CRAC channel components Orai1 or STIM1, exhibit severely impaired histamine release and leukotriene production, reduced TNF-␣ secretion, and an inability to mount a subcutaneous anaphylactic response (Baba et al., 2008; Vig et al., 2008) .
Specific inhibitors of the Ca 2+ signaling pathway are potential therapeutics for various immune and allergic diseases. As experimental tools, they could also facilitate molecular identification of mechanisms of Ca 2+ mobilization, particularly those governing CRAC channel gating. Unfortunately, blockers, such as SK&F 96365, econazole, and 2-aminoethyldiphenylborate, have IC 50 values in the micromolar range and are non-specific (Braun et al., 2003; Chung et al., 1994; Franzius et al., 1994; Ma et al., 2002; Peppiatt et al., 2003; Prakriya and Lewis, 2001; Schindl et al., 2002; Wu et al., 2000; Zitt et al., 2004) .
A number of groups have defined pyrazole derivatives exemplified by BTP2 that specifically block T-cell receptor (TCR)-induced Ca 2+ entry and Ca 2+ -dependent cytokine production (Djuric et al., 2000; Trevillyan et al., 2001; Ishikawa et al., 2003; Mercer et al., 2010a,b; Zitt et al., 2004) . As mast cell activation and degranulation is critically dependent on increases in intracellular Ca 2+ , compounds that inhibit this process would be useful as potential therapeutics for allergies and asthma. However, limited work has been done to further characterize the structural requirements for the pharmacological efficacy of these pyrazole-derived compounds, such as BTP2. (Di Capite and Parekh, 2009 ). Here, we have investigated the effect of BTP2 on activation of RBL-2H3 cells and bone marrow-derived mast cells (BMMC), as well as in vivo in a murine system, to evaluate the therapeutic potential of this compound for the treatment of mast cell-exacerbated diseases. Additionally, we provide a structure-activity relationship analysis of derivatives of BTP, defining the active portion of the BTP2 parent compound.
Experimental procedures

Cell culture and reagents
RBL-2H3 cells (American Type Culture Collection, Manassas, VA, USA) were cultured at 37 • C in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 15% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, 100 g/mL streptomycin, and 1% minimal essential medium non-essential amino acid solution. Mouse BMMCs were grown from femoral marrow cells of C57BL/6 mice as previously described with a few changes (Iyer and August, 2008) . In brief, bone marrow cells were obtained from 6 to 10-week-old mice and cultured in DMEM, supplemented with 10% FBS, 100 U/mL penicillin, 100 g/mL streptomycin, 100 M nonessential amino acids, 1 mM sodium pyruvate, 1 mM glutamine, 50 M 2-␤-mercaptoethanol (2-ME), IL-3 (10 ng/mL), and Stem Cell Factor (SCF, 50 ng/mL). Cells were passaged every two days by replating the cells in fresh medium. BMMCs were used for experiments after 4-8 weeks of culture (>95% mast cells) and were routinely >95% positive for cell surface expression of FcRI and c-kit. BTP2 (YM-58483; N-(4-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide) was purchased from CalBiochem, while other derivatives were synthesized as previously described (Djuric et al., 2000; Mercer et al., 2010b) . Both 2-aminoethoxydiphenyl borate (2-APB) and ≥99.9% anhydrous dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. For all experiments, DMSO was utilized for vehicle control purposes at a maximum concentration of 1 L/mL (∼14 M or 1:1000 dilution).
Measurements of intracellular calcium
[Ca 2+ ] i was measured using the Ca 2+ -reactive fluorescent probe Fura-2 acetoxymethylester (Fura-2AM) as previously described (Iyer and August, 2008) . First, cells were pretreated with 1 M BTP2 or vehicle for 1 h at 37 • C and, thereafter, washed with Ringer's Solution (155 mM NaCl, 4.5 mM KCl, 2 mM MgCl 2 , 10 mM dextrose, 5 mM HEPES, pH 7.4), supplemented with 1 mM CaCl 2 . Cells were loaded with 1 M Fura-2AM at a concentration of 10 7 cells/mL in Ca 2+ -supplemented Ringer's Solution for 1 h in the dark. Cells were then washed, resuspended in Ca 2+ supplemented Ringer's Solution, and the [Ca 2+ ] i of 5 × 10 5 cells was monitored using a Photon Technology International Quantamaster Spectrofluorometer. Fluorescence of Fura-2AM was monitored at room temperature. [Ca 2+ ] i was expressed as the ratio (relative fluorescence, RF) of Fura-2AM fluorescence at 510 nM caused by the two excitation wavelengths (340 nm/380 nm). [Ca 2+ ] i in BMMCs was measured using the Ca 2+ indicator Fluo-4 (Molecular Probes). BMMCs were sensitized with mouse IgE anti-dinitrophenyl (DNP) at a concentration of 1 g IgE anti-DNP/2 × 10 6 cells/mL in medium starved of IL-3 and SCF overnight, washed, and resuspended in factor-starved media. Then, the cells were treated with BTP2 (1 M), 3T5M-P, or vehicle for 1 h at 37 • C and loaded with Fluo-4 according to manufacturer's instructions. Subsequently, the cell suspension was supplemented with 2 mM CaCl 2 . The [Ca 2+ ] i of 1.25 × 10 6 cells was monitored using a FC500 Benchtop Cytometer. RF of Fluo-4 was measured at 494 nm when excited by 488 nm of light at room temperature. [Ca 2+ ] i was expressed as the RF of Fluo-4. Mean calcium post-stimulation was calculated as the mean of [Ca 2+ ] i ratiometric Fura-2AM or Fluo-4 RF measurements post-stimulation after sub-tracting the mean of baseline measurements pre-treatment. Peak calcium post-stimulation was calculated as the maximum [Ca 2+ ] i ratiometric Fura-2AM or Fluo-4 RF measurement post-stimulation after subtracting the mean of respective pre-treatment baseline measurements.
Western blotting
BMMCs were sensitized with 1 g mouse IgE anti-DNP/mL overnight, incubated with 1 M BTP2 or vehicle for 30 min at 37 • C, washed with phosphate-buffered saline (PBS) solution once, and finally challenged with 100 ng DNP-human serum albumin (HSA)/mL for indicated times (0-60 min). After challenge, the cells were lysed in RIPA lysis buffer supplemented with phosphatase inhibitors on ice. To quantitate the protein concentration of whole cell lysates, the bicinchoninic acid (BCA) protein assay (Pierce Biotechnology, Rockford, IL) was performed. Subsequently, polyacrylamide gels were loaded with 20-25 g protein per well (depending upon the experiment), and SDS-PAGE and western blotting were performed as previously described (Iyer and August, 2008) . Blots were probed with the following antibodies: anti-phospho-Erk1/2 (Thr 202 , Tyr 204 ), anti-phospho-SAPK/JNK (Thr 183 , Tyr 185 ), anti-phospho-p38 (Thr 180 , Tyr 182 ), and anti-c-fos (all from Cell Signaling Technology, Beverly, MA), followed by horseradish peroxidase (HRP)-linked goat anti-mouse or goat antirabbit Ig. HRP-linked anti-phospho-tyrosine was also used. Blots were stripped and reprobed with anti-␤-actin control antibodies. Blots were developed in chemiluminescent reagents and exposed to X-ray film. Densitometric analysis of the western blots was performed with ImageJ software, and the data was standardized to the level of ␤-actin.
Cytokine secretion assay
Analysis of cytokine secretion by BMMCs was performed as previously described (Iyer and August, 2008) , except that cells were also incubated in the presence of 1 M BTP2 or vehicle for 30 min on ice in Tyrode's buffer prior to stimulation. In brief, cells were washed and sensitized with or without mouse IgE anti-DNP (1 g/mL) in the absence of IL-3 or SCF overnight to remove exogenous IL-3. Thereafter, the cells were washed and resuspended in Tyrode's buffer. Cells were then incubated in the presence of 1 M BTP2 or vehicle for 30 min on ice in Tyrode's buffer and, afterwards, stimulated in medium starved of IL-3 and SCF in V-bottom 96-well culture plates (2 × 10 5 cells/150 L). Cells were stimulated with 50 nM phorbol myristic acid (PMA) and 500 nM ionomycin in the presence or absence of 1 M BTP2. Alternatively, cells were stimulated with 15 g rat anti-mouse IgE/mL or 100 ng DNP-HSA/mL in the presence or absence of 1 M BTP2. Cytokines in cell culture supernatants were measured using a Milliplex MAP immunoassay according to the suppliers' instructions. Within the assay sensitivities, mouse interleukin (IL)-2, IL-3, IL-4, IL-6, IL-13, tumor necrosis factor (TNF-␣), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were detected. IL-17 and IFN-␥ were not detected. Cytokine concentrations are reported in pg/mL units.
Analysis of NFAT localization
RBL-2H3 cells were cultured in glass bottom 6-well plates (2 × 10 5 cells/2 mL) overnight. For DNP-HSA stimulation, cells were sensitized with 1 g mouse IgE anti-DNP/mL overnight, washed, and resuspended in factor-starved media. Then, the cells were treated with 1 M BTP2 or vehicle for 30 min at 37 • C, stimulated with 50 nM PMA and 500 nM ionomycin or 100 ng/mL DNP-HSA for 45 min at 37 • C, and washed with PBS once. The cells were immediately fixed and permeabilized in a 50:50 methanol:acetone mixture for, at least, 15 min at −20 • C. The cells were subsequently washed with PBS three times, blocked with normal rat serum for 2 h at room temperature, and stained with Alexa Fluor 488-conjugated mouse IgG anti-Nuclear Factor of Activated T-cells, cytoplasmic 1 (NFATc1) (Santa Cruz Biotechnology, Inc.) overnight at 4 • C. Then, the cells were stained with TO-PRO-3 for the identification of localization of the nucleus. After staining, cells were observed using an Olympus Fluoview 1000 confocal microscope for fluorescence at 519 nm with an excitation wavelength of 488 nm. At a 100× magnification, images were captured at 0.2 m slices as Z-plane stacks. Data was analyzed with Autodeblur and Autovisualize X licensed software for deconvolution and 3-D image processing.
Quantitative real-time PCR analysis
BMMCs (5 × 10 6 cells) were treated with 1 M BTP2 or vehicle and cultured for 2 days. Total RNA was prepared from the treated populations, using a RNeasy Mini Kit (Qiagen Sciences, MD). Complementary DNA (cDNA) was generated using Ready-To-Go You-Prime First-Strand Beads (GE Healthcare, Buckinghamshire, UK) as per the manufacturer's protocol. Quantitative PCR was performed with the ABI 7300 Real-Time PCR System using Taqman gene expression assay probes for IL-4, IL-6, and TNF-␣, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a housekeeping gene (Applied Biosystems, Branchburg, NJ). Data was analyzed using the comparative C T (threshold cycle) method. Expression of IL-4, IL-6, and TNF-␣ was normalized based on the levels of mRNA for GAPDH and set relative to a calibrator sample. The normalized relative gene expression levels of samples were then compared with the expression level of vehicle-treated populations, set as 1.
Degranulation assays
RBL-2H3 cells were seeded at 2 × 10 5 per well (in 1 mL) of a 12-well cell culture plate and cultured overnight. In some cases, the cells were treated with BTP2, 2-APB (at 50 M), BTP2 derivatives (at the indicated concentrations or 1 M), or vehicle for 30 min at 37 • C and subsequently challenged with 500 nM ionomycin for 30 min at 37 • C. Alternatively, the cells were sensitized with 1 g mouse IgE anti-ovalbumin (OVA)/mL for 3 h at 37 • C. The cells were washed with PBS, treated with BTP2, BTP2 derivatives, or vehicle for 30 min at 37 • C, and then treated with 10 g rat anti-mouse IgE in a final volume of 1 mL medium, supplemented with BTP2, BTP2 derivatives, or vehicle for 30 min at 37 • C. Mast cell degranulation was quantitatively measured using a flow cytometric annexin-V binding assay (Demo et al., 1999) . After stimulus, RBL-2H3 cells were washed with pre-chilled PBS twice and subsequently stained with annexin-V-phycoerythrin (PE) at a dilution of 1:20 in binding buffer (commercially available as a part of the annexin-V-PE kit (BD Pharmingen) for 15 min at room temperature. The cells were analyzed using a FC500 Benchtop Cytometer. Degranulation was calculated as a percentage of the mean fluorescence intensity (MFI) of PE fluorescence of live RBL-2H3 cells, challenged in the presence of negative control (vehicle) medium, after subtracting background release (% degranulation).
Degranulation was also determined by measuring the levels of secreted ␤-hexosaminidase. RBL-2H3 cells or BMMCs were treated as described above, except that after activation, ␤-hexosaminidase activity in the supernatants was determined spectrophotometrically. In brief, 50 L of supernatant samples and 80 L of p-nitrophenyl-N-acetyl-␤-d-glucosamide (pNAG) solubilized in 0.05 M citrate buffer (pH 4.5) were added to the wells of a flatbottom 96-well plate. Color was allowed to develop for 30 min at 
37
• C. The enzymatic reaction was terminated with the addition of 200 L 0.05 M sodium carbonate buffer (pH 10.0). Absorbances at 415 nm were measured in a microplate reader. Cells were lysed with 1% Triton-X, and the extracts were analyzed for endogenous ␤-hexosaminidase activity (total − test). The ␤-hexosaminidase activity in unstimulated cells (spontaneous) was subtracted from the enzyme activity of the stimulated cells (test). The percentage of ␤-hexosaminidase released into each supernatant (% of total) was calculated using the following formula: ␤-hexosaminidase secretion (% of total) = (test − spontaneous)/(total − spontaneous) × 100. Degranulation was calculated as a percentage of the percentage released into each supernatant of total ␤-hexosaminidase (% of total) for BMMCs, challenged in the presence of negative control (vehicle) medium, after subtracting background release (% degranulation).
In vivo histamine release assay
Analysis of in vivo histamine release was determined as previously described (Iyer and August, 2008) . In brief, C57BL/6 mice (n = 3 per group, 8 weeks old) were sensitized with 1 g of mouse IgE anti-DNP via intraperitoneal injection overnight. Twelve hours post-sensitization, mice were treated with 10 mg BTP2/kg (∼50 L in PBS per mouse) or vehicle (DMSO, 50 L in PBS) as appropriate via intraperitoneal (i.p.) injection. One hour post treatment, mice were challenged with 50 g DNP-HSA (solubilized in 100 L PBS), which was delivered via intravenous injection. Control mice were sensitized with mouse IgE anti-DNP, treated with DMSO or BTP2, and were challenged with PBS alone (i.e. no antigen). 3 min post-challenge, blood was collected by cardiac puncture and stored at 4 • C until centrifugation was performed for the preparation of serum samples. Histamine was determined using a Beckman Coulter EIA Histamine Assay. All experiments were carried out in accordance with the regulations of IACUC at The Pennsylvania State University.
Statistical analysis
Data represent the mean ± standard error mean (SEM) of three independent experiments. The concentration causing 50% inhibition (IC 50 ) was calculated using non-linear regression analysis. The statistical significance was analyzed by Student's t-test (unpaired t-test, two-tailed) or by two-way ANOVA. Values of p < 0.05 were considered significant. All data analyses were performed using FlowJo or GraphPad Prism 5. C57BL/6 mice were sensitized with mouse IgE anti-DNP overnight, then treated with BTP2 (BTP2, 10 mg/kg) or vehicle (DMSO) for 1 h. Mice, treated with BTP2 or vehicle, were then challenged with DNP-HSA or PBS (as a control) for 3 min. Serum histamine concentration levels were then determined and data are expressed as the mean ± SEM, n = 8 except for control mice treated with BTP and no antigen, n = 3. *p < 0.05 vs. vehicle. Fig. 4 . BTP2 inhibits cytokine secretion of PMA/ionomycin-activated BMMCs. BMMCs were pretreated with BTP2 (1 M) or vehicle (DMSO) for 30 min, then stimulated with PMA and ionomycin. 8 and 24 h after stimulation, the concentration of the indicated cytokines was determined. Data are expressed as the mean ± SEM of technical non-independent replicates, representative of 3 independent experiments. *p < 0.05 vs. Vehicle.
Results
Effects of BTP2 on FcRI-mediated signaling in RBL-2H3 cells and BMMCs
Increases in [Ca 2+ ] i , triggered through the FcRI by IgE and allergen is necessary for the functional responses of mast cells. To analyze the possibility that BTP2 has the potential to inhibit Ca 2+ mobilization in mast cells, Ca 2+ signals in the presence or absence of BTP2 were compared. We first used RBL-2H3 cells which have been used extensively as a mast cell model to study FcRI signaling. These cells were pre-treated with BTP2 (1 M) or vehicle (DMSO) for 30 min and, then, analyzed for calcium responses, as described in Section 2, following stimulation. These initial studies with RBL-2H3 cells involved stimulation with the established Ca 2+ ionophore ionomycin, which can activate mast cell degranulation, as well as cytokine secretion, downstream (in the presence of the phorbol ester PMA) of the FcRI (Gomperts et al., 1980; Gertler and Pecht, 1988; Plaut et al., 1989) . We found that BTP2, at a 1 M concentration, significantly reduced intracellular Ca 2+ following stimulation by ionomycin (Fig. 1A) . Moreover, analysis of peak Ca 2+ responses showed a significant difference in this parameter (Fig. 1A) . Because ionomycin is not a physiological stimulus, we next tested whether Ca 2+ responses following more physiological stimuli via the FcRI were also inhibited by BTP2. In these experiments, we used anti-IgE, as well as the antigen specific IgE anti-DNP along with DNP-HSA, for the activation of primary sensitized bone marrow-derived mast cells (BMMCs). These BMMCs were pre-treated with BTP2 (1 M) or vehicle for 30 min, then stimulated with mouse anti-DNP IgE and rat anti-mouse IgE or antigen DNP-HSA for the indicated time period in the presence of CaCl 2 . Data summarized in Fig. 1A and C reveal that BTP2 inhibited the Ca 2+ response in these BMMCs following FcRI aggregation, with the Ca 2+ peak significantly inhibited regardless of stimulation method (Fig. 1B-C) .
By contrast, BTP2 did not affect FcRI-triggered tyrosine phosphorylation of cellular proteins in BMMCs (Fig. 2A) . Activation of Erk, JNK, and p38 MAPK pathways was also not affected by BTP2 treatment (Fig. 2B-D, respectively) . Finally, expression of c-Fos, which is dependent upon activation of Erk, was not altered by BTP2 treatment (Fig. 2E) . Thus, BTP2 does not grossly affect phosphorylation events immediately downstream of the FcRI.
BTP2 inhibits degranulation in RBL-2H3 cells
Mast cell degranulation is a highly regulated Ca 2+ -dependent process (Melicoff et al., 2009) . As BTP2 inhibits Ca 2+ mobilization in RBL-2H3 cells and BMMCs (Fig. 1) , we next determined if mast cell degranulation could be inhibited by BTP2. For these experiments, we used an annexin-V binding assay, as described in Section 2. RBL-2H3 cells were pretreated with BTP2 or vehicle, at a 1 M concentration, and then stimulated with ionomycin for 30 min, followed by the analysis of degranulation. We found that BTP2 significantly reduced ionomycin-induced degranulation (Fig. 3A) . This inhibition occurred in a dose-dependent fashion, with an IC 50 value of 23 nM (Fig. 3B) . Comparative analysis of population-based measurements of the secretion of the granulederived enzyme ␤-hexosaminidase between BTP-treated cells and those that were treated with vehicle alone revealed inhibition of ionomycin-induced degranulation upon pre-treatment with BTP2, thereby validating the results generated through the annexin-V binding assay (Supplemental Fig. 1) . Furthermore, BTP2 could also significantly reduce degranulation induced by FcRI crosslinking with anti-IgE antibodies. In these experiments, RBL-2H3 cells were sensitized with mouse IgE anti-OVA, pretreated with vehicle or BTP2 (1 M) for 30 min, and finally stimulated with rat anti-mouse IgE for 30 min. Our results indicate that BTP2 significantly reduced degranulation induced by FcRI as well (Fig. 3C) . BTP2 is therefore an effective inhibitor of mast cell degranulation induced through the FcRI.
BTP2 inhibits histamine release in mice in response to antigenic challenge
To further characterize the effects of BTP2 on the mast celldegranulation, we analyzed the effect of BTP2 on histamine release in vivo. Mice were sensitized with mouse IgE anti-DNP (1 g) 12 h prior to being pre-treated with 10 mg BTP2/kg or vehicle that was delivered intraperitoneally. These mice were then challenged with DNP-HSA an hour later to stimulate mast cell degranulation. Three minutes post-challenge with DNP-HSA, mice were sacrificed and serum collected and assayed for histamine. Control mice were exposed to anti-DNP IgE, but they were left unexposed to antigen to ensure that the measured responses were antigen-specific. The results show that BTP2 significantly reduces histamine release upon antigenic stimulation in vivo (Fig. 3D) . In summary, this data provides strong support for the idea that BTP2 is a potent inhibitor of mast cell degranulation in vivo.
3.4. BTP2 inhibits NFAT nuclear localization and cytokine secretion in mast cells BTP2 was originally reported to inhibit IL-2 production in activated Jurkat T-cells and human CD4 + T-cells, as well as IL-4 and IL-5 production in antigen-stimulated murine Th2 clone D10.G4.1 cells (Djuric et al., 2000; Ishikawa et al., 2003; Trevillyan et al., 2001; Zitt et al., 2004; Yoshino et al., 2007) . BTP2 also inhibits NFAT activation in Jurkat T-cells and primary human T-cells (Djuric et al., 2000; Ishikawa et al., 2003; Trevillyan et al., 2001; Zitt et al., 2004) . Because secretion of these cytokines is regulated differently in mast Fig. 5 . BTP2 inhibits cytokine secretion of IgE/anti-IgE-activated mast cells. BMMCs were sensitized with mouse anti-DNP IgE, pretreated with BTP2 (1 M) or vehicle (DMSO) for 30 min, and then stimulated rat anti-mouse IgE. 8 and 24 h after stimulation, the concentration of the indicated cytokines was determined. Data are expressed as the mean ± SEM of technical non-independent replicates, representative of 3 independent experiments. *p < 0.05 vs. vehicle. Fig. 6 . BTP2 inhibits cytokine secretion of IgE/antigen-mediated activation of mast cells. BMMCs were sensitized with mouse anti-DNP IgE, pretreated with BTP2 (1 M) or vehicle (DMSO) for 30 min, and then stimulated with DNP-HSA (100 ng/mL). 8 and 24 h after stimulation, the concentration of the indicated cytokines was determined. Data are expressed as the mean ± SEM of technical non-independent replicates, representative of 3 independent experiments. *p < 0.05 vs. vehicle. Fig. 7 . BTP2 inhibits stimulus-induced NFAT nuclear translocation. (A) RBL-2H3 cells were pretreated with BTP2 (1 M) or vehicle (DMSO) for 30 min prior to stimulation for 45 min with ionomycin or (B) mouse anti-DNP IgE and DNP-BSA (100 ng/mL). Cells were fixed and permeabilized, and NFATc1 localization determined by confocal microscopy. The nucleus was identified using TO-PRO-3 staining, and nuclear localization of NFAT is evident by the yellow nuclear staining (red plus green). White bars indicate 40 m. Representative data of 3-5 independent experiments is shown. cells in certain cases (Monticelli et al., 2004 (Monticelli et al., , 2005 Solymar et al., 2002; Bert et al., 2007) , we tested whether the cytokine secretion of BMMCs is affected by BTP2. BMMCs were stimulated with PMA and ionomycin in the presence or absence of BTP2, and supernatants were analyzed for IL-2, IL-3, IL-4, IL-13, TNF-␣, and GM-CSF. As illustrated in Fig. 4 , BTP2 inhibited the secretion of IL-2, IL-3, IL-4 and TNF-␣ from BMMCs at 8 and 24 h post stimulation. While little IL-13 was detected at the 8 h time point, BTP2 inhibited IL-13 secretion at the 24 h (Fig. 4) . By contrast, BTP2 significantly inhibited ionomycin-induced secretion of GM-CSF at the 24 h time point (Fig. 4) .
We also analyzed cytokine secretion in sensitized BMMCs stimulated with anti-IgE. We found that there was little production of IL-2 and IL-13 up to 24 h post-stimulation; however, BTP2 pretreatment inhibited the secretion of IL-3, IL-4, IL-6, TNF-␣, and GM-CSF (Fig. 5) . Similar results were obtained for IL-4, IL-6 and TNF-␣ when sensitized BMMCs were stimulated with DNP-HSA (Fig. 6) .
Because the cytokines that were inhibited by BTP2 are regulated, in part, by NFAT (Savignac et al., 2007; De Boer et al., 1999) and NFAT activation and nuclear translocation is dependent upon increases in cytosolic Ca 2+ , we examined the effect of BTP2 on NFAT localization in stimulated RBL-2H3 cells. Cells were stimulated with ionomycin, and NFAT localization was examined. Alternatively, sensitized RBL-2H3 cells were stimulated with DNP-HSA. These experiments show that BTP2 inhibited ionomycin-induced, as well as antigen-IgE/FcRI-induced, NFAT nuclear translocation ( Fig. 7A  and B) .
We noted that BTP2 treatment completely suppressed the release of IL-2 and IL-3 but partially inhibited the secretion of IL-4, IL-6, and TNF-␣ (Figs. 4-6 ). To further elucidate the mechanism of inhibition responsible for this observation, we examined the effect of BTP2 on mRNA transcript levels for IL-4, IL-6 and TNF-␣ under steady state conditions in BMMCs. As illustrated in Fig. 8 , BTP2 treatment did not significantly inhibit the levels of preformed mRNA transcripts for these cytokines suggesting that BTP2 inhibits cytokine production primarily via its effects upon de novo transcription that is regulated by NFAT or other Ca 2+ -sensitive transcription factors during the late phase of mast cell activation through the IgE receptor.
3.5. The trifluoromethyl group at the C3 position is required for the effect of BTP2
To determine which moiety within the BTP2 molecule is important for its activity, we performed limited structure-activity relationship studies of the BTP2 parent compound. We synthesized a series of BTP2 derivatives that have retained the core structure shared by all members of the BTP class of compounds but have been altered by replacing the electron-withdrawing trifluoromethyl groups of the BTP ring with less bulky electron-donating methyl groups (5T3M-P: 5-trifluoromethyl-3-methyl-pyrazole or 3T5M-P: 3-trifluoromethyl-5-methyl-pyrazole), deleting a single trifluoromethyl at either the C5 or C3 position (3T-P or 5T-P), deleting the trifluoromethyl groups entirely (Pyrazole, Pyr), or replacing both trifluoromethyl groups with methyl groups (3M5M-P) (Fig. 9A) . In addition, the remaining ring of BTP2 not shared by all members of the BTP class of compounds was replaced with the ring structure characteristic of BTP1 for these BTP2 derivatives (Kiyonaka et al., 2009) (Fig. 9A) . Accordingly, BTP1 was also tested. The BTP2 parent compound and its derivatives (1 M) were tested for their ability to inhibit degranulation in BMMCs upon ionomycin stimulation. BTP1 and BTP2 were indistinguishable in their ability to inhibit degranulation (Fig. 9B) . In addition, Pyr did not suppress degranulation; however, 5T3M-P and 3T5M-P significantly reduced degranulation in comparison to vehicle-treated cells (Fig. 9B) . However, 5T3M-P only inhibited degranulation by approximately 25%, whereas 3T5M-P was almost as potent as the parent BTP2 compound (Fig. 9B) . Indeed, a derivative with only a single trifluoromethyl group at the C3 position (3T-P) was able to inhibit degranulation, while one with only a trifluoromethyl group at the C5 (5T-P) position was not (Fig. 9B) . Finally, replacing both trifluoromethyl groups with methyl groups (in 3M5M-P) gave similar results as complete lack of the trifluoromethyl groups (pyrazole) (Fig. 9B) . The known calcium influx inhibitor 2-APB was used as a control demonstrating that this compound could also inhibit the response (Fig. 9B ). 3T5M-P inhibited ionomycin-induced degranulation with an IC 50 of 25 nM (Fig. 9C) , and in line with this finding, 3T5M-P significantly inhibited DNP-HSA-IgE/FcRI-induced calcium increases in BMMCs ( Fig. 9D and E) . These results suggest that the trifluoromethyl group at the C3 position of the pyrazole compound is critical for the inhibitory activity of BTP2 on degranulation.
Discussion
BTP2 has been characterized as a selective blocker of storeoperated Ca 2+ entry. We investigated the effect of BTP2 on mast cell function using the RBL-2H3 cell line and BMMCs in vitro, as well as in in vivo murine models, to evaluate its therapeutic potential in mast cell-mediated diseases. We show that BTP2 inhibits activation-induced increases in intracellular Ca 2+ responses. In addition, we show that BTP2 inhibits IgE and antigen-induced degranulation in vitro and histamine release in vivo, as well as activation-induced cytokine secretion in vitro. Finally, we show that the 3-trifluoromethyl group on the pyrazole ring is critical for the activity of BTP.
Sustained intracellular Ca 2+ increase is integral for allergeninduced mast cell activation. The activation of mast cells leads to the release of preformed mediators that are stored in cytoplasmic granules. These mediators include histamine, serine proteases (tryptase and chymase), carboxypeptidase A, and proteoglycans (Stone et al., 2003) . The effects of BTP2 on mast cell degranulation and cytokine secretion in vitro, as well as histamine release in vivo, suggest that this compound could modulate the effect of histamine on smooth muscle contraction, endothelial cell function, nerve endings, and mucous secretion. This agrees with other studies suggesting that BTP2 may be efficacious in models of respiratory anaphylaxis in Fig. 8 . BTP2 does not affect preformed cytokine mRNA expression. BMMCs were pretreated with BTP2 (1 M) or vehicle (DMSO) for 2 days and levels of IL-4, IL-6, and TNF-␣ were quantified. Data are expressed as the mean ± SEM of duplicate experiments. Fig. 9 . The 3-trifluoromethyl group is critical for BTP2 activity. (A) Structures of BTP2 and derivatives (BTP1; BTP2; Pyrazole: Pyr; 3-trifluoromethyl-5-methyl-pyrazole: 3T5M-P; 3-trifluoromethyl-pyrazole: 3T-P; 5-trifluoromethyl-3-methyl-pyrazole: 5T3M-P; 5-trifluoromethyl-pyrazole: 5T-P; 3-methyl-5-methyl-pyrazole: 3M5M-P). (B) BMMCs were pretreated with vehicle, 2-APB (at 50 M), or BTP analogs (at 1 M) and then stimulated with ionomycin. Degranulation was determined as indicated in Section 2. (C) RBL-2H3 cells were pretreated with 3T5M-P at the indicated concentrations Cells were then stimulated with ionomycin and degranulation determined as in Fig. 3 . (D) BMMCs were pretreated with 3T5M-P (1 M) or vehicle for 30 min, then stimulated with mouse IgE anti-DNP and DNP-HSA (100 ng/mL). Calcium responses were determined as in Fig. 1 . Representative data of 3-6 experiments is shown. (E) Mean calcium increase. Data are expressed as the mean ± SEM of 3 independent experiments. *,**p < 0.05 vs. vehicle. guinea pigs. In these models, BTP2 was able to inhibit increased bronchoconstriction and airway hyperresponsiveness (Ohga et al., 2008; Stone et al., 2003) .
Sustained elevations in [Ca 2+ ] i are also essential for the production and secretion of cytokines by mast cells, which can modulate subsequent immune responses (Di Capite and Parekh, 2009 ). The ability of BTP2 to inhibit cytokine secretion in BMMCs is likely due to reduced NFAT nuclear translocation since this transcription factor is essential for the expression of many cytokine genes in mast cells (Klein et al., 2006; Monticelli et al., 2004) . Interestingly, BTP2 treatment completely suppressed ionomycin-induced, as well as FcRI mediated, secretion of IL-2 and IL-3 but partially inhibited secretion of IL-4, IL-6 and TNF-␣. In mast cells, TNF-␣ and IL-4 can be expressed from both preformed mRNA as well as newly transcribed mRNA (Gessner et al., 2005; Stone et al., 2003) . Indeed, BTP2 treatment did not affect the levels of preformed IL-4 and TNF-␣ mRNA. In addition, BTP2 did not affect preformed levels of IL-6 mRNA. This suggests that translation of preformed mRNA for TNF-␣ and IL-4 in BMMCs is likely not affected by increases in [Ca 2+ ] i . On the other hand, de novo transcription that is regulated by NFAT or other Ca 2+ -sensitive transcription factors is likely affected by BTP2.
We also found that while BTP2 could significantly inhibit FcRImediated GM-CSF secretion, it was not as effective in inhibiting the secretion of this cytokine when the cells were stimulated with PMA and ionomycin, suggesting that this cytokine may be regulated differently and that its expression may not have as stringent a requirement for [Ca 2+ ] i increase. Indeed, analysis of the regulation of GM-CSF in transgenic mice has revealed multiple cis-acting elements that regulate this cytokine in T cells and mast cells (Bert et al., 2007) . This analysis reveals that, in addition to NFAT, other transcription factors, such as AP-1, Sp-1, GATA1, and GATA2 can be differentially used in different cell types to regulate GM-CSF expression (Bert et al., 2007) . Thus, while both FcRI-and PMA and ionomycin-mediated activation of mast cells result in GM-CSF secretion, they may act using slightly different combinations of transcription factors, with FcRI activation being more calciumdependent and thus more potently inhibited by BTP2.
Similar to the effects of BTP2 on WT BMMCs, BMMCs from mice lacking either Orai1 or STIM1 produce weak Ca 2+ signals in response to agonist (Baba et al., 2008; Vig et al., 2008) . These BMMCs are characterized by severely impaired histamine release, decreased leukotriene production, reduced TNF-␣ secretion, and a dysfunctional subcutaneous anaphylactic response. Therefore, Ca 2+ entry through CRAC channels is essential for mast cell function (Baba et al., 2008; Di Capite and Parekh, 2009; Vig et al., 2008) . Here, our profiling of the effects of BTP2 on mast cell activation and downstream responses suggests that BTP2 acts in a similar pathway. Our recent characterization of an interaction between BTP2 and the actin-regulating protein drebrin and the resultant discovery of a novel role for drebrin as a mediator of store-operated Ca 2+ entry further implies such a mechanism of action (Mercer et al., 2010b) . Further analysis of the role of drebrin in calcium signaling and mast cell function will reveal insights into the mechanism behind this process.
We also explored the structure-activity relationship between BTP2 and mast cell degranulation. Our study indicates that the trifluoromethyl groups at positions C3 and C5 of the pyrazole compound play roles in the mechanism of action of the BTP2 parent compound, with the trifluoromethyl group at C3 being more critical for the inhibitory activity of BTP2. While the 3T5M-P and 3T-P derivatives inhibited activation induced degranulation in BMMCs, the 5T3M-P, 5T-P, Pyr, and 3M5M-P derivatives were much less potent. These observed activities are similar to those reported by Kiyonaka et al. for pyrazole compounds that target the TRPC3 channel. This group recently showed that bulky functional groups at the 3,5-positions of the pyrazole may be important for the inhibition of Ca 2+ mobilization via the TRPC3 channel (Kiyonaka et al., 2009) . In this work, Kiyonaka et al. characterized the activity of a BTP derivative that substitutes the 3,5-bis(trifluoromethyl)pyrazole group with an ethyl-3-trifluoromethyl-pyrazole-4-carboxylate group in the BTP2 parent compound (4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate). This compound selectively inhibited the TRPC3 channel and was a more potent inhibitor of NFAT in cardiac myocytes than BTP2. This work also showed that the 3,5-bis(trifluoromethyl)pyrazole group or a trichloroacrylic amide group is critical for the selectivity for TRPC5 or TRPC3, respectively (Kiyonaka et al., 2009 ). This suggests that the pyrazole group provides a molecular scaffold with which to develop inhibitors of calcium signaling (Kiyonaka et al., 2009 ). These analyses suggest that the attachment of bulky and/or electronwithdrawing groups on the pyrazole ring of such molecules, particularly in the C3 position, is important for their ability to inhibit Ca 2+ mobilization. Collectively these studies indicate that BTP2 and its derivatives provide a solid molecular framework for a new generation of small molecule inhibitors for the treatment of bronchial asthma, allergies, and other mast cell-mediated diseases.
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